Market Highs: GW Pharmaceuticals Breaks Out Pending FDA Review
Chart: Tradingview Last Tuesday, April 17, GW Pharmaceuticals (GWPH), known for its development of cannabis-derived medications, broke out of its downtrend in anticipation that its latest drug, Epidiolex—a treatment for childhood epilepsy—may favorably be reviewed and...
GW Pharma shares surge on FDA briefing document that hints at approval of cannabis-derived drug
Authored by Emma Court via MarketWatch GW Pharmaceuticals PLC shares surged 10.3% in heavy Tuesday morning trade after the release of positive briefing documents for a Food and Drug Administration advisory committee meeting regarding the company’s...
10 Cryptocurrencies to Watch in Q2 2018
Authored by John Bardinelli via Investinblockchain Q1 2018 was bloody. The whole crypto market went for a slide with heavy hitters like Bitcoin and Ethereum dropping considerably. While some investors have been left reeling, those actually working on the technology...
THE US BUDGET DEFICIT EXPLODED BY $600 BILLION IN THE LAST 6 MONTHS
Might the US have a debt funding crisis soon? Check out the latest Monthly Treasury Statement. The US collected $210.8 Billion in receipts. $88 Billion from individual income tax; $98 Billion in Social Security and payroll tax; $5 Billion in corporate tax; and $20...
Recent Comments